Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 9,669 shares of the firm's stock in a transaction that occurred on Tuesday, December 27th. The shares were sold at an average price of $15.02, for a total transaction of $145,228.38. Following the sale, the chief executive officer now directly owns 173,166 shares of the company's stock, valued at approximately $2,600,953.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Dipal Doshi also recently made the following trade(s):
Get
Entrada Therapeutics alerts:
- On Thursday, December 29th, Dipal Doshi sold 400 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.01, for a total transaction of $6,004.00.
- On Monday, November 28th, Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.91, for a total transaction of $27,820.00.
- On Thursday, October 27th, Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $21.66, for a total transaction of $43,320.00.
- On Monday, October 24th, Dipal Doshi sold 2,342 shares of Entrada Therapeutics stock. The stock was sold at an average price of $19.30, for a total transaction of $45,200.60.
- On Thursday, October 20th, Dipal Doshi sold 811 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.01, for a total transaction of $14,606.11.
Entrada Therapeutics Price Performance
Shares of Entrada Therapeutics stock opened at $13.52 on Friday. The company's fifty day simple moving average is $18.00 and its 200-day simple moving average is $14.64. The stock has a market capitalization of $424.66 million, a PE ratio of -4.33 and a beta of -0.95. Entrada Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $24.38.
Entrada Therapeutics (NASDAQ:TRDA – Get Rating) last issued its quarterly earnings results on Monday, November 7th. The company reported ($0.80) earnings per share for the quarter. As a group, research analysts anticipate that Entrada Therapeutics, Inc. will post -3.08 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of TRDA. Tower Research Capital LLC TRC purchased a new position in shares of Entrada Therapeutics during the 3rd quarter valued at $40,000. Bank of New York Mellon Corp lifted its stake in shares of Entrada Therapeutics by 60.6% during the 1st quarter. Bank of New York Mellon Corp now owns 21,933 shares of the company's stock valued at $206,000 after buying an additional 8,276 shares in the last quarter. Fred Alger Management LLC purchased a new position in shares of Entrada Therapeutics during the 3rd quarter valued at $283,000. Walleye Capital LLC purchased a new position in shares of Entrada Therapeutics during the 1st quarter valued at $419,000. Finally, State Street Corp lifted its stake in shares of Entrada Therapeutics by 10.3% during the 3rd quarter. State Street Corp now owns 33,294 shares of the company's stock valued at $525,000 after buying an additional 3,100 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company's stock.
Wall Street Analysts Forecast Growth
TRDA has been the subject of a number of research analyst reports. William Blair reaffirmed an "outperform" rating on shares of Entrada Therapeutics in a research report on Friday, October 14th. The Goldman Sachs Group lifted their price target on shares of Entrada Therapeutics from $13.00 to $18.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 8th.
About Entrada Therapeutics
(Get Rating)
Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
Featured Stories
- Get a free copy of the StockNews.com research report on Entrada Therapeutics (TRDA)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
